Menu
Genomill’s vision is to be a leader in the transformation of precision diagnostics with the ultimate goal of enabling the full potential of liquid biopsies across the world.
Genomill is a pioneering precision diagnostics company with a mission to democratize the use of liquid biopsies for oncology, infectious disease detection and beyond, by removing the barriers for global access.
We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our proprietary Geno1® pre-sequencing platform, enabling significant improvements in costs, performance and scalability.
Our proprietary and patented (US patent nr: 20220298569 and 20220298566) Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation.
It truly provides means for vertical progress and enables fundamental improvements in cost, accuracy, turn-around-time and scalability. It unlocks the future.
We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term collaboration partnerships within oncology and other verticals – infectious diseases, NIPT, antibiotic resistance.
